Blueprint Medicines to Report Third Quarter 2024 Financial Results on Wednesday, October 30, 2024
Blueprint Medicines (NASDAQ: BPMC) has announced that it will host a live conference call and webcast on Wednesday, October 30, 2024, at 8:00 a.m. ET to report its third quarter 2024 financial results and provide a corporate update. Interested parties can access the live conference call by dialing 833-470-1428 (domestic) or 404-975-4839 (international) and referring to conference ID 387547.
A webcast of the call will also be available under the 'Events and Presentations' section of the company's Investors & Media webpage. The archived webcast will be accessible on Blueprint Medicines' website approximately two hours after the conference call and will remain available for 30 days following the call.
Blueprint Medicines (NASDAQ: BPMC) ha annunciato che ospiterà una conferenza telefonica in diretta e un webcast mercoledì 30 ottobre 2024, alle 8:00 ET per riportare i suoi risultati finanziari del terzo trimestre 2024 e fornire un aggiornamento aziendale. Le parti interessate possono accedere alla conferenza telefonica componendo il numero 833-470-1428 (nazionale) o 404-975-4839 (internazionale) e facendo riferimento all'ID della conferenza 387547.
Un webcast della chiamata sarà disponibile anche nella sezione 'Eventi e Presentazioni' della pagina web degli Investitori & Media dell'azienda. Il webcast archiviato sarà accessibile sul sito di Blueprint Medicines circa due ore dopo la conferenza telefonica e rimarrà disponibile per 30 giorni dopo la chiamata.
Blueprint Medicines (NASDAQ: BPMC) ha anunciado que llevará a cabo una conferencia telefónica en vivo y un webcast el miércoles 30 de octubre de 2024, a las 8:00 a.m. ET para informar sobre sus resultados financieros del tercer trimestre de 2024 y proporcionar una actualización corporativa. Las partes interesadas pueden acceder a la conferencia telefónica en vivo marcando 833-470-1428 (nacional) o 404-975-4839 (internacional) y haciendo referencia al ID de conferencia 387547.
Un webcast de la llamada también estará disponible en la sección 'Eventos y Presentaciones' de la página web de Inversores y Medios de la compañía. El webcast archivado estará accesible en el sitio web de Blueprint Medicines aproximadamente dos horas después de la conferencia telefónica y permanecerá disponible durante 30 días después de la llamada.
Blueprint Medicines (NASDAQ: BPMC)는 2024년 10월 30일 수요일 오전 8시 ET에 2024년 3분기 재무 결과를 보고하고 기업 업데이트를 제공하기 위해 라이브 컨퍼런스 콜과 웹캐스트를 개최한다고 발표했습니다. 관심 있는 당사자는 833-470-1428 (국내) 또는 404-975-4839 (국제)로 전화하여 컨퍼런스 ID 387547를 참조하여 라이브 컨퍼런스 콜에 접속할 수 있습니다.
해당 호출의 웹캐스트는 회사의 투자자 및 미디어 웹페이지의 '이벤트 및 프레젠테이션' 섹션에서도 이용할 수 있습니다. 아카이브된 웹캐스트는 컨퍼런스 콜 이후 약 2시간 후에 Blueprint Medicines 웹사이트에서 접근할 수 있으며, 호출 후 30일 동안 이용 가능합니다.
Blueprint Medicines (NASDAQ: BPMC) a annoncé qu'elle organisera une conférence téléphonique en direct et un webcast le mercredi 30 octobre 2024, à 8h00 ET pour faire état de ses résultats financiers du troisième trimestre 2024 et fournir une mise à jour sur l'entreprise. Les parties intéressées peuvent accéder à la conférence téléphonique en direct en composant le 833-470-1428 (national) ou le 404-975-4839 (international) et en se référant à l'identifiant de conférence 387547.
Un webcast de l'appel sera également disponible dans la section 'Événements et Présentations' de la page Investisseurs & Médias de l'entreprise. Le webcast archivé sera accessible sur le site de Blueprint Medicines environ deux heures après la conférence téléphonique et restera disponible pendant 30 jours après l'appel.
Blueprint Medicines (NASDAQ: BPMC) hat angekündigt, dass am Mittwoch, den 30. Oktober 2024, um 8:00 Uhr ET eine Live-Konferenzschaltung und ein Webcast stattfinden werden, um ihre Finanzergebnisse für das dritte Quartal 2024 bekannt zu geben und ein Unternehmensupdate bereitzustellen. Interessierte Parteien können die Live-Konferenzschaltung unter der Nummer 833-470-1428 (national) oder 404-975-4839 (international) erreichen und dabei auf die Konferenz-ID 387547 verweisen.
Ein Webcast des Anrufs wird ebenfalls im Abschnitt 'Veranstaltungen und Präsentationen' der Webseite für Investoren und Medien des Unternehmens verfügbar sein. Der archivierte Webcast wird etwa zwei Stunden nach der Konferenzschaltung auf der Website von Blueprint Medicines zugänglich sein und 30 Tage nach dem Anruf verfügbar bleiben.
- None.
- None.
To access the live conference call, please dial 833-470-1428 (domestic) or 404-975-4839 (international) and refer to conference ID 387547. A webcast of the call will also be available under "Events and Presentations" in the Investors & Media section of the Blueprint Medicines website at http://ir.blueprintmedicines.com/. The archived webcast will be available on Blueprint Medicines' website approximately two hours after the conference call and will be available for 30 days following the call.
About Blueprint Medicines
Blueprint Medicines is a global, fully integrated biopharmaceutical company that invents life-changing medicines. We seek to alleviate human suffering by solving important medical problems in two core focus areas: allergy/inflammation and oncology/hematology. Our approach begins by targeting the root causes of disease, using deep scientific knowledge in our core focus areas and drug discovery expertise across multiple therapeutic modalities. We have a track record of success with two approved medicines, including AYVAKIT®/AYVAKYT® (avapritinib) which we are bringing to patients with systemic mastocytosis (SM) in the
View original content to download multimedia:https://www.prnewswire.com/news-releases/blueprint-medicines-to-report-third-quarter-2024-financial-results-on-wednesday-october-30-2024-302275822.html
SOURCE Blueprint Medicines Corporation
FAQ
When will Blueprint Medicines (BPMC) report its Q3 2024 financial results?
How can investors access Blueprint Medicines' (BPMC) Q3 2024 earnings call?
Where can I find the webcast for Blueprint Medicines' (BPMC) Q3 2024 earnings call?
How long will the archived webcast of Blueprint Medicines' (BPMC) Q3 2024 earnings call be available?
